Research
Hormonal
Anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists, have shown safety and weight loss efficacy in patients with heart failure with preserved ejection fraction.
Clinicians may consider glucagon-like peptide-1 receptor agonists for weight management in patients with heart failure with preserved ejection fraction.
StrongSupportsmedium confidence
clinical trials data supporting the safety and efficacy of treating obesity in patients with HF is currently limited to patients with HF with preserved ejection fraction, but do confirm safety and weight loss efficacy in this patient population.
Why this rating
The claim is based on clinical trial data.
Source
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Josephine Harrington et al. · Circulation Heart Failure · 2024
DOI 10.1161/circheartfailure.124.011518
reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →